Seegene Strengthens Its Position in Europe with New French Subsidiary

Seegene Expands European Operations with New French Subsidiary

On December 5, 2025, Seegene, Inc., renowned for its pivotal role in the field of molecular diagnostics (MDx), announced the opening of a new subsidiary in France. This strategic move marks a significant step in Seegene's efforts to enhance its European footprint, following its successful establishments in Italy and Germany.

With France now being the ninth overseas sales subsidiary for Seegene, the company aims to leverage this new base to accelerate growth and bolster its customer engagement in one of Europe's largest molecular diagnostics markets. According to market research, France is estimated to have an MDx market value of approximately EUR 600 million, accounting for about 15% of the total MDx market in Europe. This makes it the second-largest market in the continent, trailing only Germany, which commands a 19% share.

The establishment of this subsidiary is particularly timely given the rising demand for diagnostic solutions related to sexually transmitted infections (STIs), gastrointestinal infections, and respiratory virus detection. Seegene is poised to harness this growing demand by expanding its sales of existing product lines while introducing a wider portfolio that includes diagnostics for cervical cancer and other multiplex categories.

Daniel Shin, the Executive Vice President and Chief Global Sales and Marketing Officer at Seegene, emphasized the importance of a localized approach, stating that quickly delivering innovative products in response to the efficiency needs of laboratories is crucial in maintaining competitiveness in the French healthcare landscape. The new subsidiary not only aims to improve customer service but also enhances the ability to adapt quickly to market demands and regulatory environments.

Furthermore, the French subsidiary provides a strategic advantage in the European rollout of Seegene's developing technologies such as CURECA™, an automated PCR system, and STAgora™, a platform focused on real-time diagnostic data analytics and predictive insights. These innovations are expected to play a significant role in meeting market needs and advancing diagnostic capabilities.

Seegene's growing international presence, including its global distribution network spanning 90 distributors in 94 countries, highlights its commitment to expanding its reach. Currently, international sales contribute approximately 93% of Seegene's total revenue, with Europe accounting for about 63%. This trend underscores the European market's significance as a key driver in the company's global expansion strategy.

Seegene's legacy over the past 25 years has established it as a leader in syndromic real-time PCR technology. This expertise truly came to the forefront during the COVID-19 pandemic, where the company provided over 340 million tests across more than 100 countries. Its multiplex testing technology, which can simultaneously detect 14 pathogens in a single tube, underlines the company's innovative capabilities.

As Seegene embraces this new chapter with its French subsidiary, the implications for the European MDx market are profound. The company is not just aiming for sales growth but also seeking to enhance the overall diagnostic landscape in Europe with its high-quality solutions and robust customer relations.

For more information, visit Seegene's official website or follow their updates on LinkedIn.